The dose of docetaxel is currently calculated based on body surface area and does not reflect the pharmacokinetic, metabolic potential or genetic background of the patients. The influence of genetic variation on the clearance of docetaxel was analysed in a two-stage analysis. In step one, 583 single-nucleotide polymorphisms (SNPs) in 203 genes were genotyped on samples from 24 patients with locally advanced non-small cell lung cancer. We found that many of the genes harbour several SNPs associated with clearance of docetaxel. Most notably these were four SNPs in EGF, three SNPs in PRDX4 and XPC, and two SNPs in GSTA4, TGFBR2, TNFAIP2, BCL2, DPYD and EGFR. The multiple SNPs per gene suggested the existence of common haplotypes associated with clearance. These were confirmed with detailed haplotype analysis. On the basis of analysis of variance (ANOVA), quantitative mutual information score (QMIS) and Kruskal-Wallis (KW) analysis SNPs significantly associated with clearance of docetaxel were confirmed for GSTA4, PRDX4, TGFBR2 and XPC and additional putative markers were found in CYP2C8, EPHX1, IGF2, IL1R2, MAPK7, NDUFB4, TGFBR3, TPMT (2 SNPs), (Po0.05 or borderline significant for all three methods, 14 SNPs in total). In step two, these 14 SNPs were genotyped in additional 9 samples and the results combined with the genotyping results from the first step. For 7 of the 14 SNPs, the results are still significant/borderline significant by all three methods: ANOVA, QMIS and KW analysis strengthening our hypothesis that they are associated with the clearance of docetaxel.
Introduction
Multiple modes of cell death generate the overall tumour response to treatment. The resulting mechanisms of cell death are determined by the mode of action of the drug, the dose regimen used and the genetic background of the cells within the tumour, with apoptosis being considered to be the prevailing mechanism in response to chemotherapy. Docetaxel, a semi-synthetic taxane with antineoplastic effect, functions primarily through inducing stability on microtubule structures. Docetaxel promotes tubulin assembly and inhibits depolymerisation, thereby disrupting the balance of the microtubular network. 1, 2 As a result, a mitotic catastrophe occurs, cells undergo arrest in the G2-M phase and if irreversible, the changes lead to cell death. 1 Docetaxel is used in the clinic, either alone or in combination with other chemotherapeutic agents, for the treatment of breast, gastric, prostate, head and neck, ovarian as well as lung cancer. 3 Chemotherapeutic drugs such as docetaxel administered at subtoxic doses may act by means of a radio-sensitisation mechanism 4 and the combination of low-dose chemotherapy and thoracic radiotherapy has been shown to improve the prognosis of locally advanced non-small cell lung cancer (NSCLC). 5 The clearance of docetaxel is a result of its metabolism, a complex process involving among other different isoforms of the CYP3A enzyme and excretion, docetaxel is a substrate for the efflux membrane-localised transporter P-gp, encoded by the gene ABCB1. 6 Recent published results, however, imply that metabolism may be more important for elimination of docetaxel than transport (as reviewed in Baker et al. ). A pharmacokinetic model of docetaxel clearance identifies several co-variants of drug clearance: body surface area, a 1 -acid glycoprotein (AAG) levels and liver function (as assessed by the combined level of Alanine amino transferase and Aspartate amino transferase). The model was shown to be a better predictor of docetaxel clearance than a Naïve predictor (assuming no co-variants) only in selected subsets of the population. 7 Both chemotherapy and radiation therapy exert their antineoplastic effect by either directly attacking cellular macromolecules, including DNA, or indirectly, by producing reactive oxygen species (ROS) and their by-products. The generated ROS induces a stress response activating multiple pathways in the cells (for example, the mitogenactivated protein kinase (MAPK) pathway) as well as transcription factors such as Nfr2, which regulates the expression of genes containing the antioxidant response element. This cis-acting regulatory element has been discovered in the sequence of important cellular antioxidant and detoxifying enzymes (for example, the phase II drug metabolising enzymes GSTs, NQOs and UGTs) and illustrates how the pathways directly involved in the therapeutic mode of action of the drug directly affect the metabolism and clearance of the drug. [8] [9] [10] Generated ROS have also been shown to repress expression of genes such as tumour necrosis factora (in certain cell types) and CYPs suggesting a feed-back mechanism in the transcriptional regulation of these ROS producing enzymes. [11] [12] [13] [14] Therefore, the genes selected here to create the genotype profile of patients treated with radiation therapy and/or chemotherapy are all involved in regulating the redox level in the cells and in signalling or in DNA damage repair caused by ROS. 15 Pharmacokinetic calculations of clearance level for docetaxel were performed and correlated to the patient's genetic profile. The effect of 583 single-nucleotide polymorphisms (SNPs) on the excretion of docetaxel was studied. We computed the association between each genotype locus and each measured docetaxel clearance value for each patient, and searched the resulting association matrix for statistically significant structures. A selected subset of 14 SNPs identified in the analysis to be associated with the clearance of docetaxel was genotyped in an independent sample set and the data reanalysed with these samples included to further validate our findings.
Materials and methods
In this study, we genotyped 24 Norwegian patients with locally advanced NSCLC. The stage of disease was IIIA or IIIB for the patients receiving low-dose docetaxel (n ¼ 5) and IIIB and IV for the group of patients receiving high-dose docetaxel (n ¼ 19). Of the 24 patients, pharmacokinetic data were available for 22, 17 receiving high-dose docetaxel (100 mg m -2 , administered every 3 weeks) without irradiation and 5 receiving low-dose docetaxel (20 mg m -2 , administered once every week) with irradiation to the chest wall. To validate our findings we collected samples from additional nine patients with NSCLC wherein information regarding clearance of docetaxel was available. The dose of docetaxel was determined by body surface area and liver function. 16 For the analysis of the genetic effect on the clearance of docetaxel performed here, no sub-division of the patients based on whether they received radiotherapy treatment or not, was performed. Information on level of AAG was available for all patients with data on clearance of docetaxel. The blood samples for genetic analysis were collected after proper informed consent was obtained and the project was approved by the local ethical committee. Leukocyte DNA was isolated from thawed blood containing EDTA using chloroform/phenol extraction followed by ethanol precipitation using the Applied Biosystems (Foster City, CA, USA) 340A Nucleic Acid Extractor according to standard protocol.
Docetaxel clearance
Docetaxel was administered as a 1-h infusion and blood samples were collected in EDTA tubes at time points; 0 (before infusion), 30 min (midway in the infusion of docetaxel), 55 min (end-point of infusion, represents maximum dose), 90 min, 2, 3, 6, 10, 20 and 25 h. The collected blood samples were pre-processed and stored at À70 1C until analysed. All patients provided written informed consent. Docetaxel was extracted from human plasma by solid phase extraction, and detected by absorbance at 227 nm after separation by reversed phase high performance liquid chromatography, described in Andersen et al. 17 Individual pharmacokinetic parameters were calculated using the pharmacokinetic software PK Solutions 2.0 (Summit Research Services, Montrose, CO, USA). Area under the concentration-time curve was determined by trapezoid calculation using measured concentrations. Systemic docetaxel clearance (l h -1 m -2 ) was calculated as dose divided by area under the curve.
SNP mining and genotyping
The candidate genes for SNP analysis were selected from around 4000 MEDLINE entries and different databases (Online Mendelian Inheritance in Man and the Human Genome Organisation, John Hopkins University, Baltimore, MD, USA) as described in Edvardsen et al. 15 to create the genotype profile of all genes involved in the regulation of the redox level in the cells, ROS-mediated signalling and repair of DNA-damage caused by ROS. Genes important for the metabolism of xenobiotics have been included in the original gene list such as the Genetic variation influencing docetaxel clearance H Edvardsen et al cytochrome P450 family (CYP1B1, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2E1, CYP2F1, CYP3A4 and CYP3A7) as well as ABCB1 and ABCC1. In addition, the list of candidate genes contained several members of the GST family (GSTA2, GSTA3, GSTA4, GSTM1, GSTM5, GSTP1 and GSTT2) as well as EPHX1 and EPHX2 and UDP glycosyltransferases all of which are reported to be involved in the metabolism of xenobiotics. Briefly, each of the candidate genes extracted from PubMed resources was matched with the official Human Genome Organisation gene name and information regarding sequence variation was obtained. The annotation of each SNP was followed in several databases and data on its frequency in Caucasian population were collected. Approximately, 4000 SNPs could be identified in the initial 233 candidate genes by computer annotation. SNP selection was performed based on putative function and SNP frequencies. We performed actual genotyping of 1030 of these SNPs in 193 individuals (including the 24 NSCLC patients in which docetaxel clearance was studied (this paper). Of these 725 (B69%) were successfully genotyped. Another 38 SNPs were not in Hardy-Weinberg equilibrium (B5%) in the total cohort of 193 individuals and these SNPs were excluded from further analysis. In the subset of the 24 NSCLC patients studied here, further 104 (B14.3%) of the 725 genotyped SNPs had either a minor allele frequency of o5% or a low success rate and were excluded from the analysis leaving 583 SNPs for studies of the effect of SNPs on the excretion of docetaxel. As discussed in Edvardsen et al., 15 the low success rate in this study could reflect the fact that this was a pilot experiment with no optimisation and that the users had no previous experience with the GenomeLab SNPstream UHT genotyping system. The genotype procedure includes multiplexing of assays for 12 SNPs and this relatively high degree of multiplexing with the expected drop-outs is also likely to have had an influence on our success rate.
Statistical analysis of SNP-pharmacokinetic associations
An association matrix, whose entries represent the P-values of association for every SNP/clearance pair 18 was computed. For each pair (s,t) of SNP and docetaxel clearance value, we calculated an association score and a corresponding P-value P st using either of the three methods described below. Given a significance threshold 0oPo1, we state that s is associated with t if P st op.
Analysis of variance (ANOVA).
For each SNP locus we computed the one-way ANOVA P-value for the clearance vector and grouping of the samples based on SNP locus genotypes. 19 The null hypothesis here is that the clearance level distributions are the same, regardless of the genotype class.
Kruskal-Wallis (KW) test. This one-way ANOVA is a nonparametric rank-based method that tests the null hypothesis that independent samples from two or more groups come from distributions with equal medians, and returns the P-value for that test. The test is an extension of the Mann-Whitney U-test. The data are assumed to come from continuous distributions that are identical.
Quantitative mutual information score (QMIS). For a SNP locus s and a vector q of clearance values, let G be a partition of samples induced by the genotype values at locus s. For a clearance level threshold p, let C p be a partition of samples defined by the qop and qXp. The mutual information score (MIS) is the difference between the entropy of the partition C p and the conditional entropy of C p given G:
, where H is the entropy function. The QMIS is defined to be the maximum possible MIS, that is, QMIS(C,G) ¼ max min(q) pppmax(q) MIS(C p ,G). A P-value for the mutual information score can be computed exactly by an efficient exhaustive approach. 18, 20 The null hypothesis here is that genotype values have the same distribution, regardless of the clearance levels.
Leave one out cross validation (LOOCV). LOOCV was used to further confirm strong associations with level of clearance, above or below median of 20.5 (l h -1 m -2 ) providing the possibility to assess the combined effect of sets of SNPs. We performed 10 runs of LOOCV hiding two samples at each step of the analysis, using forward sequential search. 18 The number of times each SNP appears as a predictor is summarised. (Similar to the methods described in Hedenfalk et al.
21
).
Haplotype analyses
Linkage disequilibrium estimation was performed using Haploview (Cambridge, MA, USA). Haploview estimates the maximum-likelihood values of the four gamete frequencies, from which the D 0 , LOD and r 2 calculations are derived. 22 Pathway analyses Pathway analysis was performed using PathwayStudio v4.0 (Rockville, MD, USA), using the ResNet core 1.0 (Rockville, MD, USA) database that contains curated data of high confidence.
Results

Prediction of clearance above or below median
The range of docetaxel clearance was 10-34 with a median of 20.5 (l h -1 m -2 ) for all cases combined and a median of 24 and 17 for the group of patients receiving high and low dose of docetaxel respectively. In the model by Bruno et al., 7 the covariates of docetaxel clearance include body surface area, AAG levels and liver function. In this study, we did not adjust for any covariates other than body surface area and liver function, which was adjusted for in the dosage scheme. Analysing a total of 547 patients, the investigators found that their model only surpassed the Naïve predictor (assuming no covariates) in extreme subset of patients such as patients with AAG level above the 90th percentile-2.27 g l -1 . In our study, 2 of the 22 patients had AAG level above the 90th percentile for our data set and for the rest of the patients no adjustment would be necessary.
Analysing clearance above or below median the mutual information score revealed a distinct difference in genotype distribution for 18 SNPs in 14 genes (Table 1) . A total of 9 of these 18 SNPs were found to reside in regions reported to be amplified or deleted in docetaxel resistant cell lines. 23 In a recent study, we reported the association between SNPs in blood and intra-tumoral mRNA expression in 50 women with breast cancer, 24 and seven out of these nine SNPs were found to be associated with level of transcript either in cis or trans, Table 2 . The difference in genotype distribution for these 18 SNPs is shown in the heat map in Figure 1a (for example, PRDX4, GSTA4, EPHX1, EGF and CYP2C8) with a stacked diagram of the distribution of the genotypes for these SNPs shown in Figure 1b . Several of these genes, indicated by red circle in the figure, are reported to have a role in the Kyoto encyclopaedia of genes and genomes pathway 'metabolism of xenobiotics by cytochrome P450'.
We observed that in many cases the SNPs associated with clearance of docetaxel reside in the same gene suggesting the existence of common haplotypes associated with clearance. Most notably these are four SNPs in EGF, three SNPs in each of PRDX4 and XPC, and two SNPs in GSTA4, TGFBR2, TNFAIP2, BCL2, DPYD, EGFR. Analysis of linkage disequilibrium between the SNPs in these genes reveals high level of linkage disequilibrium as exemplified in Figure 2 . Interestingly, associations of SNPs in interacting genes such as EGF and EGFR, as well as different subfamilies of Cytochrome P450 and different receptors of TGFbeta were found, suggesting gene-gene interactions.
An alternative LOOCV analysis revealed 20 SNPs in 19 genes that were scored as predictors for docetaxel from 1 to 7 times out of 10, the most frequent being SNPs in EGF (7 hits out of 10), TNFAIP2 (5 hits), GSTA4 (5 hits), ALOX15B (4 hits), PRKCABP (4 hits) and PRDX4 (3 hits), (Table 3) . Two different SNPs in GSTA4 were scored as predictors, rs316128 (4 hits) and rs1032419 (1 hit), which are in complete linkage disequilibrium, Figure 2 . Indicates that the SNP reside in a region reported to be deleted in docetaxel resistant cell lines, none of the regulatory SNPs were found to be located in amplified regions. 23 The last column lists the transcripts associated with these SNPs and also included is information as to whether this regulation is in cis or in trans, (SNPs in blood and expression in tumours).
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Significant associations by both ANOVA score and QMIS SNPs significantly associated with clearance of docetaxel by both ANOVA and QMIS were found in the following genes CYP2C8, EPHX1, GSTA4, IGF2, IL1R2, MAPK7, NDUFB4, PRDX4, TGFBR2, TGFBR3, TPMT (two SNPs) and XPC (two SNPs) ( Table 4 ). The statistical association between the clearance level and the SNPs identified by both ANOVA and QMIS was also analysed by the KW test and 12 of the 14   10  10  11  14  16  16  17  18  18  19  20  21  22  24  25  26  26  27  27  27  28 
Chr4
Chr6 Figure 2 Level of linkage disequilibrium (LD) in EGF and GSTA4. All SNPs genotyped for these genes have been included in the analysis with SNPs significantly associated with clearance below or above the median of 20.5 (l h -1 m -2 ) circled in red. The LD plots are created using Haploview and the colour code on plot follows the standard colour scheme for Haploview: white
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. Numbers on top of the plot are the reference sequence id (rs-number) of the included SNPs with the distance between them indicated on the white bar above. The numbers in the squares on the LD plot are the D' value (only the decimals are shown)-D' of 1 are not listed. QMIS seeks to establish the threshold of the quantitative parameter such that the difference in distribution of genotypes between the resulting partitions will be of maximal value, the last column indicates this threshold for each given SNP.
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Bold numbers indicate a significant association by that given method, italic numbers indicate a borderline significant association.
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identified SNPs were also found significant by this test. The two SNPs with conflicting results were located in TPMT and MAPK7 (Table 4 , panel a). A heat map shows the distribution of the patients with most different combinations of genotypes into the groups of above and below median (Figure 3) . In this study, the SNPs are sorted according to ANOVA P-value with the most significant listed first. For these 14 SNPs, the criteria were set such that the association will be found significant by both QMIS and ANOVA and the highest P-value o0.05. We further studied the genes harbouring SNPs positively associated with clearance to see how they are functionally related. An overview of the shortest path between the genes associated with clearance was composed by Pathway Studio v4.0 (Figure 4) . This pathway analysis revealed the direct interactions between the clearance-associated genes (framed with blue ovals on figure) and between the clearanceassociated genes and other genes not included in this study (TP53, Sp1 and MAPK1), upstream off our candidate genes.
Our statistical method QMIS seeks to establish the threshold of the quantitative parameter such that the difference in distribution of genotypes between the resulting partitions will be of maximal value. This results in somewhat different thresholds for each SNP (Table 4 , column 'clearance threshold'). Nevertheless, these different thresholds oscillated around the median (20. ). Observing the ANOVA distribution of the clearance levels for all patients with a given genotype distinct differences can be found ( Figure 5 ). Individuals homozygous for the variant allele of rs1382368 in XRCC4 (Figure 5a ) had high clearance as well as those homozygous carriers of variant rs780995 in the in PIK3CA (Figure 5b ) compared with the individual homozygous for the more prevalent allele and the individuals with a heterozygous genotype. In other instances, only the presence of the variant allele was sufficient to exert phenotype. In the case of rs528329 of PRDX4, even heterozygous individuals had a different phenotype manifested as higher clearance in which the levels for the heterozygotes and the homozygote minor allele frequency were similar (Figure 5c ) and lower clearance for the heterozygotes and homozygote of the minor allele frequency allele in rs2234922 in EPHX1 (Figure 5d ).
To validate our results, samples from additional nine NSCLC patients were collected and analysed. As this represents a small sample set, the statistical analysis were performed with the combined set of 22 samples from the first round and these 9 new samples. We see that for 7 of the 14 SNPs, the results are still significant/borderline significant by all three analysis: ANOVA, QMIS and KW, 1 SNP is significant by 2 of the selected analysis, 5 SNPs are still significant/borderline significant by 1 of the methods, while only 1 SNP are no longer significant by any of the three methods (Table 4 , panel b).
Discussion
Docetaxel is one of the most effective chemotherapeutic agents in the treatment of cancer and works through destabilising the balance of the microtubule network. In addition to this primary function taxanes, docetaxel included, have other lines of action. We have adapted the illustration on the effect of antimicrotubule agents on signal transduction from Wang et al. 2 and added information on gene-gene families involved in the metabolism of xenobiotics to highlight the genes found by us to be associated with docetaxel clearance (Figure 6 ). The inclusion has been based on information on involvement in defined Kyoto encyclo -2228001   2236930   1078985   2230949   701992   2607737   795491   2253316   1032419   2234922   7886   1341164   1042865   2842951   10  10  11  14  16  16  17  18  18  19  20  21  22  24  25  26  26  27  27  27  28 Figure 4 Shortest path between genes predicted to be associated with docetaxel clearance by both ANOVA and QMIS analysis (highest P-value 0.100). Genes circled in blue are input genes. The figure is generated using Pathway Studio 4.0 with the Resnet Core database containing high confidence curated data based on the ResNet 4 database for mammals. Figure 5 Normal distribution of clearance levels corresponding to each genotype for rs1382368 (a), rs870995 (b), rs518329 (c) and rs2234922 (d) in XRCC4, PIK3CA, PRDX4 and EPHX1, respectively, together with linkage disequilibrium (LD) plots for all SNPs genotyped in these genes. The LD plots are created using Haploview and the colour code on plot follows the standard colour scheme for Haploview: white paedia of genes and genomes pathways retrieved from GeneCard, (http://www.genecards.org/index.shtml). The SNPs found associated with docetaxel clearance in this study are in genes that target both the metabolism and modes of action of docetaxel at multiple levels.
Iwao-Koizumi et al. 25 have analysed the link between expression levels in tumour biopsies from breast cancer patients before treatment and the response to docetaxel therapy. The most prominent characteristic in nonresponders was found to be elevated expression of genes controlling the cellular redox environment, that is, those of the glutathione and thioredoxin systems. These genes included GSTP1, GPX1, TXN and PRDX1 as well as GPX4 and were all subsequently confirmed in functional studies using reporter vectors. These genes are clearly involved in the clearance coupled metabolism of the drug indicating an association between ROS and clearance of docetaxel in line with our findings and may explain the resistance with lower therapeutic load in the nonresponders.
High-level, docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) have been created and studied by comparative genomic hybridisation. Genomic regions associated with resistance to docetaxel in MCF-7 were identified as amplification of chromosomes 7q21.11-q22.1, 17q23-q24.3, 18, and deletion of chromosomes 6p, 10q11.2-qter and 12p. In MDA-MB-231 cells on the other hand, a gain of chromosomes 5p, 7q11.1-q35, 9, and loss of chromosomes 4, 8q24.1-qter, 10, 11q23.1-qter, Cross-communication Figure 6 The metabolism of xenobiotics and effect of antimicrotubule agents on signal transduction adapted from Wang et al.
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. Activation of signalling pathways induces the expression of drug metabolising genes containing the antioxidant response element such as GSTs and UGTs. The increased ROS level after drug metabolism affects the expression level/function of members of the signalling pathways such as Bcl-2 as well as drug metabolising enzymes themselves. Genes given in bold harbour SNPs found associated with clearance level in our study.
12q15-q24.31, 14q and 18 were showed to be associated with docetaxel resistance. Amplification of 7q21 and loss of 10q are suggested to represent a common mechanism of acquired docetaxel resistance in breast cancer cells. 23 We observed that many of the SNPs associated with docetaxel clearance by mutual information score reside in genes located in these areas reported to be amplified or deleted in docetaxel resistant cells, such as CYP2C8 (10q23.33), CYP3A7 (7q22.1), EGF (4q25), IL8 (4q13.3), TNFAIP2 (14q32.32) and GSTA4 (6p12.1) several of which are also selected by LOOCV analysis to harbour SNPs predictive of docetaxel clearance together with PRKCABP, ALOX15B and PRDX4, and shown by us previously to influence transcription. 24 CYP3A7 is involved in the hydroxylation of retinoic acid and 16 alpha-hydroxylation of steroids, which implicates it both in normal development and carcinogenesis. 26, 27 GSTA4 on the other hand is highly effective in catalysing 4-hydroxynonenal, a commonly used biomarker for oxidative damage in tissues. 28 Both these proteins are together with CYP2C8 involved in the metabolism of xenobiotics by cytochrome P450. TNFAIP2 is induced in response to the proinflammatory molecules TNF and IL1B while PRKCABP is involved in modulating the activity of protein kinase C alpha (PRKCA) and anchoring the protein to mitochondria. 29 Allele-specific alterations have been described enforcing the effect of low-penetrance variants in genes with oncogenic or tumour suppressor potential 30 indicating that a SNP that confers an alteration in the function or level of a gene product in a deleted or amplified area may lead to loss of heterozygosity either through deletion of the ancestral or specific amplification of the variant allele.
Our study indicates that it is possible to extract a limited set of SNPs that will successfully predict an individual patient's clearance level. Ultimately, drug concentration and clearance will be used in the clinic to adjust dosage of docetaxel administered to the patients. Therefore, being able to predict beforehand whether a patient will have a high or low clearance, based on genotyping performed on germline DNA, will be of importance for clinical practise.
